Current and next-generation bleutongue vaccines

Requirements, strategies, and prospects for different field situations

Femke Feenstra, P.A. van Rijn

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)

Abstract

Bluetongue virus (BTV) causes the hemorrhagic disease bluetongue (BT) in ruminants. The best way to control outbreaks is vaccination. Currently, conventionally modified-live and inactivated vaccines are commercially available, which have been successfully used to control BT, but nonetheless have their specific shortcomings. Therefore, there is a need for improved BT vaccines.

The ideal BT vaccine is efficacious, safe, affordable, protective against multiple serotypes and enables the differentiation of infected from vaccinated animals. Different field situations require specific vaccine profiles. Single serotype outbreaks in former BT-free areas need rapid onset of protection against viremia of the respective serotype. In contrary, endemic multiple serotype situations require long-lasting protection against all circulating serotypes. The ideal BT vaccine for all field situations does not exist and balancing between vaccine properties is needed.

Many new vaccines candidates, ranging from non-replicating subunits to replicating next-generation reverse genetics based vaccines, have been developed. Some have been tested extensively in large numbers of ruminants, whereas others were developed recently and have only been tested in vitro and in mice models. Most vaccine candidates are promising, but have their specific shortcomings and advantages. In this review, current and next-generation BT vaccines are discussed in the light of prerequisites for different field situations.
Original languageEnglish
Pages (from-to)142-155
JournalCritical Reviews in Microbiology
Volume43
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint

Bluetongue
Vaccines
Ruminants
Disease Outbreaks
Bluetongue virus
Reverse Genetics
Inactivated Vaccines
Viremia
Vaccination
Serogroup

Cite this

@article{9bbcf22788c5456cb311e2eede3f9593,
title = "Current and next-generation bleutongue vaccines: Requirements, strategies, and prospects for different field situations",
abstract = "Bluetongue virus (BTV) causes the hemorrhagic disease bluetongue (BT) in ruminants. The best way to control outbreaks is vaccination. Currently, conventionally modified-live and inactivated vaccines are commercially available, which have been successfully used to control BT, but nonetheless have their specific shortcomings. Therefore, there is a need for improved BT vaccines.The ideal BT vaccine is efficacious, safe, affordable, protective against multiple serotypes and enables the differentiation of infected from vaccinated animals. Different field situations require specific vaccine profiles. Single serotype outbreaks in former BT-free areas need rapid onset of protection against viremia of the respective serotype. In contrary, endemic multiple serotype situations require long-lasting protection against all circulating serotypes. The ideal BT vaccine for all field situations does not exist and balancing between vaccine properties is needed.Many new vaccines candidates, ranging from non-replicating subunits to replicating next-generation reverse genetics based vaccines, have been developed. Some have been tested extensively in large numbers of ruminants, whereas others were developed recently and have only been tested in vitro and in mice models. Most vaccine candidates are promising, but have their specific shortcomings and advantages. In this review, current and next-generation BT vaccines are discussed in the light of prerequisites for different field situations.",
author = "Femke Feenstra and {van Rijn}, P.A.",
year = "2017",
doi = "10.1080/1040841X.2016.1186005",
language = "English",
volume = "43",
pages = "142--155",
journal = "Critical Reviews in Microbiology",
issn = "1040-841X",
publisher = "Taylor & Francis",
number = "2",

}

Current and next-generation bleutongue vaccines : Requirements, strategies, and prospects for different field situations. / Feenstra, Femke; van Rijn, P.A.

In: Critical Reviews in Microbiology, Vol. 43, No. 2, 2017, p. 142-155.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Current and next-generation bleutongue vaccines

T2 - Requirements, strategies, and prospects for different field situations

AU - Feenstra, Femke

AU - van Rijn, P.A.

PY - 2017

Y1 - 2017

N2 - Bluetongue virus (BTV) causes the hemorrhagic disease bluetongue (BT) in ruminants. The best way to control outbreaks is vaccination. Currently, conventionally modified-live and inactivated vaccines are commercially available, which have been successfully used to control BT, but nonetheless have their specific shortcomings. Therefore, there is a need for improved BT vaccines.The ideal BT vaccine is efficacious, safe, affordable, protective against multiple serotypes and enables the differentiation of infected from vaccinated animals. Different field situations require specific vaccine profiles. Single serotype outbreaks in former BT-free areas need rapid onset of protection against viremia of the respective serotype. In contrary, endemic multiple serotype situations require long-lasting protection against all circulating serotypes. The ideal BT vaccine for all field situations does not exist and balancing between vaccine properties is needed.Many new vaccines candidates, ranging from non-replicating subunits to replicating next-generation reverse genetics based vaccines, have been developed. Some have been tested extensively in large numbers of ruminants, whereas others were developed recently and have only been tested in vitro and in mice models. Most vaccine candidates are promising, but have their specific shortcomings and advantages. In this review, current and next-generation BT vaccines are discussed in the light of prerequisites for different field situations.

AB - Bluetongue virus (BTV) causes the hemorrhagic disease bluetongue (BT) in ruminants. The best way to control outbreaks is vaccination. Currently, conventionally modified-live and inactivated vaccines are commercially available, which have been successfully used to control BT, but nonetheless have their specific shortcomings. Therefore, there is a need for improved BT vaccines.The ideal BT vaccine is efficacious, safe, affordable, protective against multiple serotypes and enables the differentiation of infected from vaccinated animals. Different field situations require specific vaccine profiles. Single serotype outbreaks in former BT-free areas need rapid onset of protection against viremia of the respective serotype. In contrary, endemic multiple serotype situations require long-lasting protection against all circulating serotypes. The ideal BT vaccine for all field situations does not exist and balancing between vaccine properties is needed.Many new vaccines candidates, ranging from non-replicating subunits to replicating next-generation reverse genetics based vaccines, have been developed. Some have been tested extensively in large numbers of ruminants, whereas others were developed recently and have only been tested in vitro and in mice models. Most vaccine candidates are promising, but have their specific shortcomings and advantages. In this review, current and next-generation BT vaccines are discussed in the light of prerequisites for different field situations.

U2 - 10.1080/1040841X.2016.1186005

DO - 10.1080/1040841X.2016.1186005

M3 - Article

VL - 43

SP - 142

EP - 155

JO - Critical Reviews in Microbiology

JF - Critical Reviews in Microbiology

SN - 1040-841X

IS - 2

ER -